Burning Rock Biotech Limited (NASDAQ: BNR) is 48.48% higher on its value in year-to-date trading and has touched a low of $18.64 and a high of $32.40 in the current 52-week trading range. The BNR stock was last observed hovering at around $27.50 in the last trading session, with the day’s gains setting it 6.8% off its average median price target of $209.82 for the next 12 months. It is also 84.09% off the consensus price target high of $215.56 offered by 3 analysts, but current levels are 83.19% higher than the price target low of $204.08 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $34.30, the stock is 39.49% and 31.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing 24.73% at the moment leaves the stock 34.82% off its SMA200. BNR registered a loss of 20.65% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $25.51 and a 200-day simple moving average (SMA200) of $25.32.
The stock witnessed a 39.09% gain in the last 1 month and extending the period to 3 months gives it a 23.29%, and is 37.92% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.47% over the week and 7.22% over the month.
Burning Rock Biotech Limited (BNR) has around 753 employees, a market worth around $3.48B and $59.70M in sales. Distance from 52-week low is 84.01% and 5.86% from its 52-week high. The company has generated returns on investments over the last 12 months (20.50%).
Burning Rock Biotech Limited (BNR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Burning Rock Biotech Limited (BNR) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Burning Rock Biotech Limited is expected to release its quarterly report on 06/02/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $19.3M over the same period.The EPS is expected to shrink by -43.80% this year.
Burning Rock Biotech Limited (BNR) Top Institutional Holders
45 institutions hold shares in Burning Rock Biotech Limited (BNR), with institutional investors hold 18.89% of the company’s shares. The shares outstanding are 101.78M, and float is at 15.53M with Short Float at 2.54%. Institutions hold 18.89% of the Float.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 4.75 million shares valued at $119.03 million. The investor’s holdings represent 35.16% of the BNR Shares outstanding. As of Sep 29, 2020, the second largest holder is Casdin Capital, LLC with 1.92 million shares valued at $48.21 million to account for 14.24% of the shares outstanding. The other top investors are Matthews International Capital Management, LLC which holds 1.38 million shares representing 10.24% and valued at over $34.67 million, while Baillie Gifford and Company holds 7.50% of the shares totaling 1.01 million with a market value of $25.39 million.